# EDGAR Filing Document

**Accession Number:** 0001969686
**File Stem:** 0001104659-23-033407
**Filing Date:** 2023-3
**Character Count:** 6688
**Document Hash:** 4fc74e98e19b01226246f50710a23858
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-033407.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0001104659-23-033407

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230215

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Shustov Andrei
- **CENTRAL INDEX KEY:** 0001969686

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36598
- **FILM NUMBER:** 23740071

**MAIL ADDRESS:**
- **STREET 1:** 7 PARKLAND DRIVE
- **CITY:** MILFORD
- **STATE:** NJ
- **ZIP:** 08848
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cellectar Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001279704
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 043321804
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** (608) 441-8120

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVELOS THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20050617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COMMON HORIZONS INC
- **DATE OF NAME CHANGE:** 20040211

## Ex-24

**Exhibit 24**

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized Andrew Reed, Dexter L. Pagdilao Jr., Ara L. Lee, Sadie M. Claflin, Yunzhou Wang, Daniel Atchue and Allen Kogan, each acting singly, to prepare, execute and file on the undersigned's behalf a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the U.S. Securities and Exchange Commission (the "SEC") of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation thereunder.

This Statement further confirms that the undersigned has authorized and designated Asher M. Rubin, Istvan Hajdu, Andrea Reed, Chad Kolean, and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the SEC as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc.

The authority of Andrew Reed, Dexter L. Pagdilao Jr., Ara L. Lee, Sadie M. Claflin, Yunzhou Wang, Daniel Atchue, Allen Kogan, Asher M. Rubin, Istvan Hajdu, Andrea Reed, Chad Kolean, and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Andrew Reed, Dexter L. Pagdilao Jr., Ara L. Lee, Sadie M. Claflin, Yunzhou Wang, Daniel Atchue, Allen Kogan, Asher M. Rubin, Istvan Hajdu, Andrea Reed, Chad Kolean, and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated: March 13, 2023

Signed: <u>/s/ Andrei Shustov</u>

Print Name: Andrei Shustov, M.D.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Shustov Andrei<br><sub>(Last) (First) (Middle)</sub><br>C/O CELLECTAR BIOSCIENCES, INC.<br>100 CAMPUS DRIVE<br><sub>(Street)</sub><br>FLORHAM, NJ 07932<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Cellectar Biosciences, Inc. [ CLRB ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-02-15 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Senior Vice President, Medical_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 7181.7 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Christina Blakley, Attorney-in-fact for Andrei Shustov  
**Date:** 2023-03-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**